KPV Research Guide: The α-MSH Tripeptide Fragment in Inflammation Research

KPV is one of the smallest peptides with a dedicated research literature. Consisting of just three amino acids — lysine, proline, and valine — it is the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid signaling peptide whose effects on inflammatory pathways have been studied for decades. What makes KPV scientifically interesting is a structure-function puzzle: the fragment retains much of the parent molecule's inflammation-related signaling activity in preclinical models, while lacking the sequence responsible for α-MSH's pigmentation effects. This article reviews what the published research shows about KPV's structure, mechanisms, and experimental findings — strictly as a research-use-only reference.

Research Use Only. The material discussed here is intended solely for laboratory research. Nothing in this article constitutes medical advice, and no therapeutic claims are made. Research-grade KPV is not an approved drug product.

What Is KPV?

KPV is a tripeptide with the amino acid sequence Lys-Pro-Val and a molecular weight of approximately 342 g/mol. It corresponds to residues 11–13 of α-MSH — the final three amino acids at the hormone's C-terminus. α-MSH itself is cleaved from pro-opiomelanocortin (POMC), a precursor protein processed into several signaling peptides involved in pigmentation, appetite regulation, and immune modulation (Catania et al., 2004).

Several structural features explain why researchers study KPV separately from its parent molecule:

• Pharmacophore minimization: KPV is a textbook case of reducing a hormone to its smallest functional fragment. Structure-activity studies mapped much of α-MSH's inflammation-related activity to its C-terminal sequence, separable from the rest of the molecule (Brzoska et al., 2008).
• A missing "message sequence": Melanocortin receptor activation — including the pigmentation signaling driven by the melanocortin-1 receptor (MC1R) — depends on α-MSH's central core sequence, His-Phe-Arg-Trp (residues 6–9). KPV does not contain this sequence, which is the structural basis for its lack of melanogenic activity in research models.
• Transporter compatibility: As a tripeptide, KPV is a substrate for PepT1, the intestinal di- and tripeptide transporter — a property that gives it an intracellular route of action unusual among signaling peptides (Dalmasso et al., 2008).

Structure and Function: Keeping the Signal, Dropping the Pigmentation

The melanocortin system comprises five G protein-coupled receptors (MC1R–MC5R) with distinct tissue distributions and functions. MC1R, expressed on melanocytes as well as on immune and epithelial cells, mediates both pigmentation responses and part of α-MSH's immunomodulatory signaling. MC3R, expressed in immune cells including macrophages, is also implicated in the resolution of inflammatory responses in preclinical models (Catania et al., 2004; Catania et al., 2010).

Because KPV lacks the His-Phe-Arg-Trp core required for classical melanocortin receptor activation, its activity profile differs from the parent hormone. Dissection studies comparing α-MSH's core and C-terminal fragments found that the C-terminal peptide carries distinct, separable anti-inflammatory activity in experimental models (Getting et al., 2003). Work in MC1R-deficient mice later showed that KPV's effects in intestinal inflammation models were attenuated but not eliminated when MC1R signaling was absent — evidence that its mechanism involves both MC1R-dependent and MC1R-independent components (Kannengiesser et al., 2008). This dual character is precisely why KPV remains useful to researchers: it helps separate which parts of melanocortin biology are receptor-driven and which are not.

Mechanisms Studied in the Laboratory

NF-κB Pathway Modulation

The best-characterized intracellular action of KPV in the literature is inhibition of NF-κB activation. NF-κB is a transcription factor that controls the expression of many pro-inflammatory genes, and it is a standard readout in inflammation research. Using NF-κB reporter assays in human intestinal epithelial cell lines and human T cells, Dalmasso and colleagues reported that KPV reduced NF-κB activation and downstream pro-inflammatory cytokine secretion, alongside effects on MAP kinase signaling pathways (Dalmasso et al., 2008). Because these experiments were performed in cultured cells, they describe pathway-level interactions rather than organism-level outcomes.

PepT1-Mediated Cellular Uptake

The same research group demonstrated that KPV enters cells through PepT1 (SLC15A1), the proton-coupled transporter that normally absorbs dietary di- and tripeptides in the small intestine and is upregulated in inflamed colonic tissue in the models studied. Uptake experiments using radiolabeled substrate competition showed KPV is transported by human PepT1 expressed in both intestinal epithelial and immune cells — a mechanistic explanation for how a tripeptide can act intracellularly on NF-κB rather than only at surface receptors (Dalmasso et al., 2008). Follow-up work extended the PepT1–KPV axis to additional murine models of intestinal inflammation (Viennois et al., 2016).

Epithelial Barrier Research

A related strand of literature examines melanocortin peptides at epithelial barriers — the intestinal lining and the skin — where barrier integrity and immune signaling intersect. In Caco-2 intestinal epithelial monolayers, α-MSH was shown to protect against cytokine-induced barrier disruption, work that frames the barrier research context for its fragments (Varadi et al., 2017). KPV and related tripeptides have likewise been studied in keratinocyte and cutaneous inflammation models, where melanocortin signaling is locally active (Brzoska et al., 2008).

Key Published Research on KPV

Intestinal Inflammation Models

Kannengiesser et al. (2008), publishing in Inflammatory Bowel Diseases, evaluated KPV in two murine models of intestinal inflammation (dextran sodium sulfate colitis and a T-cell transfer model). KPV administration was associated with earlier recovery and reduced inflammatory infiltrate on histology compared with controls, and the MC1R-deficient mouse experiments in the same study informed the receptor-dependence question described above. As with all animal-model work, these findings describe preclinical observations; they do not establish effects in any clinical setting.

Transport and Intracellular Action

Il Gastroenterology study by Dalmasso et al. (2008) remains the mechanistic anchor of the field: it connected PepT1 transport, NF-κB inhibition, and reduced inflammatory readouts in two murine colitis models into a single proposed mechanism — transport into the cell, then pathway modulation from inside it. Later delivery-system research, including nanoparticle formulations designed to carry KPV to inflamed intestinal tissue in murine models, builds directly on this framework (Xiao et al., 2017).

Reviews of the Melanocortin–Inflammation Literature

Two reviews consolidate the field. Catania et al. (2004) laid out melanocortin receptor targeting as a research strategy for controlling inflammation, and Brzoska et al. (2008) reviewed α-MSH and its related tripeptides across in-vitro and in-vivo models, including the cutaneous research literature. KPV has also surfaced in recent regulatory discussions of peptide bulk substances, including the FDA Pharmacy Compounding Advisory Committee's 2026 review agenda — a further sign of sustained scientific interest in the fragment.

KPV Research Materials at NUPEPS PEPTIDES

NUPEPS PEPTIDES supplies KPV as a lyophilized research reference material:

• KPV 10MG — suited to cell-based signaling assays, transport studies, and structure-activity research programs

Each batch is supplied with a Certificate of Analysis documenting purity (≥99%) and identity verification. All materials are for research use only.

Evaluating KPV Quality in a Research Setting

Because KPV is a minimal fragment, identity verification matters: a tripeptide's activity in an assay depends entirely on the correctness of its three-residue sequence. Researchers routinely verify several quality attributes before beginning experimental work:

• Identity confirmation: Mass spectrometry should confirm the expected molecular weight (~342 g/mol) for the Lys-Pro-Val sequence.
• Purity assessment: Reversed-phase HPLC is the standard method for quantifying peptide purity; NUPEPS reports ≥99% purity on its Certificates of Analysis.
• Sequence-level scrutiny: With only three residues, there is no redundancy — an incorrect or truncated sequence is a different molecule. Batch-specific documentation, rather than a generic certificate, provides the traceability reproducible research requires.
• Lyophilized format and storage: Freeze-dried presentation supports stability; research material is stored desiccated at −20 °C per product documentation.

These practices reflect general standards in peptide research procurement and are not specific to any single supplier.

Domande frequenti

What is the amino acid sequence of KPV?

KPV is a tripeptide with the sequence Lys-Pro-Val. It corresponds to residues 11–13 of α-MSH, the C-terminal end of the 13-amino-acid parent hormone.

How does KPV differ from α-MSH?

α-MSH contains the His-Phe-Arg-Trp core sequence (residues 6–9) required for classical melanocortin receptor activation, including pigmentation signaling. KPV lacks this core. In preclinical literature, the fragment retains inflammation-related signaling activity studied in cell and animal models, without the melanogenic activity of the full hormone (Brzoska et al., 2008).

Does KPV act through melanocortin receptors?

Partly, according to the published evidence. Experiments in MC1R-deficient mice showed attenuated but not absent effects, indicating both MC1R-dependent and MC1R-independent components (Kannengiesser et al., 2008). A separate, well-documented mechanism is intracellular: KPV is transported into cells by PepT1 and modulates NF-κB signaling (Dalmasso et al., 2008).

What is PepT1, and why does it matter for KPV research?

PepT1 (SLC15A1) is the intestinal di- and tripeptide transporter. Because KPV is a tripeptide, it is a PepT1 substrate, giving it a route into intestinal epithelial and immune cells that larger peptides do not have. This transport step is central to the mechanism proposed in the literature.

What analytical documentation accompanies NUPEPS KPV?

Each batch includes a Certificate of Analysis reporting HPLC purity (≥99%) and mass spectrometry identity confirmation.

Is KPV intended for human or veterinary use?

No. NUPEPS KPV is supplied strictly as a research reference material for laboratory use only. It is not intended for human or veterinary use, and no therapeutic claims are made.

References

1. Catania A, Gatti S, Colombo G, Lipton JM. "Targeting melanocortin receptors as a novel strategy to control inflammation." Pharmacol Rev. 2004;56(1):1-29.
2. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases." Endocr Rev. 2008;29(5):581-602.
3. Getting SJ, Schiöth HB, Perretti M. "Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides." J Pharmacol Exp Ther. 2003;306(2):631-637.
4. Kannengiesser K, Maaser C, Heidemann J, et al. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflamm Bowel Dis. 2008;14(3):324-331.
5. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134(1):166-178.
6. Viennois E, Ingersoll SA, Ayyadurai S, et al. "Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model." Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357.
7. Xiao B, Xu Z, Viennois E, et al. "Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis." Mol Ther. 2017;25(7):1628-1640.
8. Varadi J, Harazin A, Fenyvesi F, et al. "Alpha-melanocyte stimulating hormone protects against cytokine-induced barrier damage in Caco-2 intestinal epithelial monolayers." PLoS One. 2017;12(1):e0170537.
9. Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S. "The melanocortin system in control of inflammation." ScientificWorldJournal. 2010;10:1840-1853.